Therapeutic Potential of Ellagic Acid in Liver Diseases
Molecules · 15.06.2025 · 30 (12) · 2596
DOI: 10.3390/molecules30122596 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 15.06.2025. Verfasst von Karolina Wojtunik-Kulesza und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Inorganic Chemistry, Medical University of Lublin, Chodźki 4a, 20-093 Lublin, Poland. Hauptthemen laut MEDLINE: Ellagic Acid, Liver Diseases. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This research was funded by Medical University of Lublin, internal grant., Medical University of Lublin.
Abstract (Originalsprache)
Ellagic acid (EA) is a natural polyphenol found in various fruits, nuts, and mushrooms. It exhibits a variety of biological activities, including potent antioxidant, anti-inflammatory, anti-obesity, and neuroprotective properties. EA exerts hepatoprotective effects through multiple mechanisms, including (1) scavenging reactive oxygen species (ROS) and enhancing endogenous antioxidant defenses (e.g., by activating Nrf2/ARE), (2) modulating inflammatory signaling pathways (e.g., inhibiting NF-κB, TNF-α, and IL-6), and (3) regulating apoptosis (e.g., downregulating the Bax/Bcl-2 ratio) and fibrosis (e.g., inhibiting TGF-β/Smad signaling). Despite its promising preclinical efficacy, the clinical applicability of EA is currently limited by its poor bioavailability. This could potentially be overcome by advanced delivery systems or by directly administering its active microbial metabolites, known as urolithins. EA and its derivatives also modulate the gut microbiota, promoting the growth of beneficial species and reducing gut permeability and hepatic inflammation. Preliminary clinical trials and other emerging evidence suggest that EA may reduce liver inflammation, oxidative stress, and metabolic dysregulation. However, more extensive human studies are needed to confirm its efficacy and safety in managing liver disease. This review highlights the therapeutic potential of EA in the treatment of liver diseases, particularly metabolic-dysfunction-associated steatotic liver disease (MASLD).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Inorganic Chemistry, Medical University of Lublin, Chodźki 4a, 20-093 Lublin, Poland.
- Department of Pharmacology, Medical University of Lublin, Radziwiłłowska 11, 20-080 Lublin, Poland.
- Chair of Comprehensive Dentistry, Medical University of Lublin, Chodżki 6, 20-093 Lublin, Poland.
- Department of Thermal Technology and Food Process Engineering, University of Life Sciences in Lublin, Głęboka 31, 20-612 Lublin, Poland.
ORCID-Profile: Karolina Wojtunik-Kulesza, Przemysław Niziński, Tomasz Oniszczuk, Maciej Combrzyński, Anna Oniszczuk
Förderung
- This research was funded by Medical University of Lublin, internal grant.
- Medical University of Lublin
Zitieren
APA
Wojtunik-Kulesza, K., Niziński, P., Krajewska, A., Oniszczuk, T., Combrzyński, M., & Oniszczuk, A. (2025). Therapeutic Potential of Ellagic Acid in Liver Diseases. Molecules, 30(12), 2596. https://doi.org/10.3390/molecules30122596
Vancouver
Wojtunik-Kulesza K, Niziński P, Krajewska A, Oniszczuk T, Combrzyński M, Oniszczuk A. Therapeutic Potential of Ellagic Acid in Liver Diseases. Molecules. 2025;30(12):2596. doi:10.3390/molecules30122596
BibTeX
@article{WojtunikKulesza2025,
author = {Wojtunik-Kulesza, Karolina and Niziński, Przemysław and Krajewska, Anna and Oniszczuk, Tomasz and Combrzyński, Maciej and Oniszczuk, Anna},
title = {Therapeutic Potential of Ellagic Acid in Liver Diseases},
journal = {Molecules},
year = {2025},
volume = {30},
number = {12},
pages = {2596},
doi = {10.3390/molecules30122596}
}
EUVIMED